Literature DB >> 6178592

Comparison of effects of leukocyte and fibroblast interferon on immunological parameters in cancer patients.

M A Lucero, H Magdelenat, W H Fridman, P Pouillart, C Billardon, A Billiau, K Cantell, E Falcoff.   

Abstract

Patients with metastatic cancer were given single intramuscular injections of 10(7) units of partially purified preparations of either leukocyte or fibroblast IFN. Serum levels of inteferon, of beta 2-microglobulin and of carcino-embryonic antigen (CEA), as well as NK activity of circulating lymphocyte, were followed over a period of 96 hr post injection. In confirmation of previous studies, levels of circulating IFN were lower after injection of fibroblast IFN than after injection of leukocyte IFN. Despite this difference in pharmacokinetics, the natural killer activity of circulating lymphocytes was enhanced with both IFNs. Levels of DEA were not influenced by the IFN injections. Leukocyte but not fibroblast IFN caused an increase in serum levels of beta 2-microglobulin in the circulation. A similar difference between leukocyte and fibroblast IFN in their ability to influence the beta 2-microglubulin system was observed in experiments on cell cultures. Only leukocyte IFN was able to cause release of beta 2-microglobulin by either leukocytes or fibroblasts.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6178592     DOI: 10.1016/0277-5379(82)90043-8

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  10 in total

1.  Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study.

Authors:  E Villa; P Trande; A Grottola; P Buttafoco; A M Rebecchi; T Stroffolini; F Callea; A Merighi; L Camellini; P Zoboli; R Cosenza; L Miglioli; P Loria; R Iori; N Carulli; F Manenti
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

Review 2.  IFN-induced modulation of histocompatibility antigens on human cells. Background, mechanisms and perspectives.

Authors:  M Hokland; P Basse; J Justesen; P Hokland
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

Review 3.  The interferon system as a basis for antiviral therapy or prophylaxis.

Authors:  A Billiau
Journal:  Antiviral Res       Date:  1985       Impact factor: 5.970

4.  Low doses of interferon alpha result in more effective clinical natural killer cell activation.

Authors:  B S Edwards; J A Merritt; R C Fuhlbrigge; E C Borden
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

5.  Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment.

Authors:  R Wejstål; G Norkrans; O Weiland; R Schvarcz; D Fuchs; H Wachter; A Fryden; H Glaumann
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

6.  Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy.

Authors:  L Tentori; M P Fuggetta; S D'Atri; A Aquino; C Nunziata; M Roselli; P Ballatore; E Bonmassar; L De Vecchis
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Pyrogenic and haematological effects of the interferon-inducing 22K factor (interleukin 1 beta) from human leukocytes.

Authors:  J van Damme; G Opdenakker; M de Ley; H Heremans; A Billiau
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

8.  Increased expression of human monocyte HLA-DR antigens and Fc gamma receptors in response to human interferon in vivo.

Authors:  J Rhodes; D H Jones; N M Bleehen
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

Review 9.  The clinical application of fibroblast interferon--an overview.

Authors:  A Billiau
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

10.  A phase I trial of recombinant gamma interferon in patients with cancer.

Authors:  K A Foon; S A Sherwin; P G Abrams; H C Stevenson; P Holmes; A E Maluish; R K Oldham; R B Herberman
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.